Cytek Biosciences, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cytek Biosciences, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $193.02M | Mar 13, 2024 |
| FY2023 | Dec 31, 2022 | $2.96M | Mar 13, 2024 |
| FY2023 | Dec 31, 2021 | $2.18M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $710.0K | Mar 1, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $201.49M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $200.45M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $193.02M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $164.04M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $127.95M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $92.84M | Mar 1, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $104.46M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $111.11M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $109.43M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $100.97M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $79.14M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $51.71M | Mar 1, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($66.54M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($6.02M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($12.15M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $2.48M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $3.03M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $19.41M | Mar 1, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($40.38M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($20.52M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($27.85M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($1.80M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $9.16M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $13.66M | Mar 1, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.47M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $39.40M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $44.15M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $34.86M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $24.44M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $13.69M | Mar 1, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.69M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $25.38M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $5.28M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($12.23M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $4.63M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $15.16M | Mar 1, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.08M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.53M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $4.65M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $9.75M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $4.36M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $1.55M | Mar 1, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $461.54M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $499.50M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $494.46M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $519.48M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $463.31M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $219.98M | Mar 17, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.80M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $103.76M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $101.39M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $93.93M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $57.92M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $41.69M | Mar 17, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $341.74M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $395.74M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $393.06M | Feb 28, 2025 |
| FY2024 | Dec 31, 2022 | $425.55M | Feb 28, 2025 |
| FY2024 | Dec 31, 2021 | $405.39M | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | ($16.03M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2019 | $41.70M | Mar 1, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.70M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $16.66M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $16.18M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $10.14M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $10.14M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $476.0K | Mar 17, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($101.74M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($35.20M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($29.18M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($17.03M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($19.61M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($22.61M) | Mar 17, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $90.85M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $98.72M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $167.30M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $296.60M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $364.62M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $165.23M | Mar 17, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Mar 13, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Mar 13, 2024 |
| FY2023 | Dec 31, 2021 | 0 | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Mar 13, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Mar 13, 2024 |
| FY2023 | Dec 31, 2021 | 0 | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 128.55M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 129.21M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 130.71M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 135.37M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 133.75M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 31.24M | Mar 17, 2022 |